相似文献
1
DREADDs: novel tools for drug discovery and development.
Drug Discov Today. 2014 Apr;19(4):469-73. doi: 10.1016/j.drudis.2013.10.018. Epub 2013 Nov 1.
2
Generation of designer receptors exclusively activated by designer drugs (DREADDs) using directed molecular evolution.
Curr Protoc Neurosci. 2010 Jan;Chapter 4:Unit 4.33. doi: 10.1002/0471142301.ns0433s50.
3
Novel designer receptors to probe GPCR signaling and physiology.
Trends Pharmacol Sci. 2013 Jul;34(7):385-92. doi: 10.1016/j.tips.2013.04.006. Epub 2013 Jun 13.
4
DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility.
Annu Rev Pharmacol Toxicol. 2015;55:399-417. doi: 10.1146/annurev-pharmtox-010814-124803. Epub 2014 Sep 25.
5
Use of Designer G Protein-Coupled Receptors to Dissect Metabolic Pathways.
Trends Endocrinol Metab. 2016 Sep;27(9):600-603. doi: 10.1016/j.tem.2016.04.001. Epub 2016 Jul 2.
6
Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein-Coupled Receptor Signaling for Fibrosis.
J Pharmacol Exp Ther. 2020 Nov;375(2):357-366. doi: 10.1124/jpet.120.000103. Epub 2020 Aug 26.
7
Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.
Genesis. 2016 Aug;54(8):439-46. doi: 10.1002/dvg.22949. Epub 2016 Jun 3.
8
A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways.
J Biol Chem. 2016 Apr 8;291(15):7809-20. doi: 10.1074/jbc.M115.702282. Epub 2016 Feb 5.
9
Use of DREADD Technology to Identify Novel Targets for Antidiabetic Drugs.
Annu Rev Pharmacol Toxicol. 2021 Jan 6;61:421-440. doi: 10.1146/annurev-pharmtox-030220-121042. Epub 2020 Aug 3.
10
DREADD: a chemogenetic GPCR signaling platform.
Int J Neuropsychopharmacol. 2014 Oct 31;18(1):pyu007. doi: 10.1093/ijnp/pyu007.
引用本文的文献
1
Neuroprotective Role of Cyclic AMP Signaling in Dopaminergic Degeneration Induced by a Parkinson's Disease Toxin, Rotenone.
NeuroSci. 2025 Mar 11;6(1):24. doi: 10.3390/neurosci6010024.
2
Neuromodulation in Small Animal fMRI.
J Magn Reson Imaging. 2025 Apr;61(4):1597-1617. doi: 10.1002/jmri.29575. Epub 2024 Sep 15.
3
Astrocytic activation increases blood flow in the adult olfactory bulb.
Mol Brain. 2024 Aug 6;17(1):52. doi: 10.1186/s13041-024-01126-1.
4
Dermal TRPV1 innervations engage a macrophage- and fibroblast-containing pathway to activate hair growth in mice.
Dev Cell. 2024 Nov 4;59(21):2818-2833.e7. doi: 10.1016/j.devcel.2024.05.019. Epub 2024 Jun 7.
5
G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery.
Signal Transduct Target Ther. 2024 Apr 10;9(1):88. doi: 10.1038/s41392-024-01803-6.
6
V2a neurons restore diaphragm function in mice following spinal cord injury.
Proc Natl Acad Sci U S A. 2024 Mar 12;121(11):e2313594121. doi: 10.1073/pnas.2313594121. Epub 2024 Mar 5.
7
Activation of cyclic AMP signaling pathway in dopaminergic neurons rescues locomotion defects in a Drosophila larval model of Parkinson's disease.
Brain Res. 2024 Jan 1;1822:148641. doi: 10.1016/j.brainres.2023.148641. Epub 2023 Oct 21.
8
Multiple Subthreshold GPCR Signals Combined by the G-Proteins Gα and Gα Activate the Egg-Laying Muscles.
J Neurosci. 2023 May 24;43(21):3789-3806. doi: 10.1523/JNEUROSCI.2301-22.2023. Epub 2023 Apr 13.
9
Chemogenetic inhibition of corticotropin-releasing factor neurons in the central amygdala alters binge-like ethanol consumption in male mice.
Behav Neurosci. 2022 Dec;136(6):541-550. doi: 10.1037/bne0000522. Epub 2022 Jun 30.
10
eIF2-dependent translation initiation: Memory consolidation and disruption in Alzheimer's disease.
Semin Cell Dev Biol. 2022 May;125:101-109. doi: 10.1016/j.semcdb.2021.07.009. Epub 2021 Jul 23.
本文引用的文献
1
Structural features for functional selectivity at serotonin receptors.
Science. 2013 May 3;340(6132):615-9. doi: 10.1126/science.1232808. Epub 2013 Mar 21.
2
Structural basis for molecular recognition at serotonin receptors.
Science. 2013 May 3;340(6132):610-4. doi: 10.1126/science.1232807. Epub 2013 Mar 21.
3
A pharmacological organization of G protein-coupled receptors.
Nat Methods. 2013 Feb;10(2):140-6. doi: 10.1038/nmeth.2324. Epub 2013 Jan 6.
4
Automated design of ligands to polypharmacological profiles.
Nature. 2012 Dec 13;492(7428):215-20. doi: 10.1038/nature11691.
5
Pharmacosynthetics: Reimagining the pharmacogenetic approach.
Brain Res. 2013 May 20;1511:6-20. doi: 10.1016/j.brainres.2012.09.043. Epub 2012 Oct 9.
6
TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.
Circ Heart Fail. 2012 Sep 1;5(5):627-34. doi: 10.1161/CIRCHEARTFAILURE.112.969220. Epub 2012 Aug 13.
7
Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.
J Med Chem. 2012 Aug 23;55(16):7141-53. doi: 10.1021/jm300603y. Epub 2012 Aug 13.
8
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.
J Neurosci. 2012 Jun 20;32(25):8532-44. doi: 10.1523/JNEUROSCI.0337-12.2012.
9
Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93. doi: 10.1073/pnas.1104807108. Epub 2011 Oct 24.
10
Biased signalling and allosteric machines: new vistas and challenges for drug discovery.
Br J Pharmacol. 2012 Mar;165(6):1659-1669. doi: 10.1111/j.1476-5381.2011.01749.x.
Zotero 插件